DDOG — long thesis

Confidence: medium · Status: active

Thesis

Datadog delivered a blowout Q1 2026: revenue $1.006B (+32% YoY), first time exceeding $1B in a Q1. Non-GAAP EPS $0.60 beat estimates significantly (+18% beat). Free cash flow was $289M with a 29% margin. Large customers ($100K+ ARR) grew 21% to ~4,550. Critically, non-AI customer revenue growth re-accelerated to mid-20s% (from 23% in Q4, 19% a year ago), proving the core observability business is structurally healthy. New logo bookings more than doubled YoY. The company landed deals with two of the world's largest AI research teams for GPU monitoring in training environments — a TAM expansion management explicitly said wasn't a market for them a year ago. FY2026 guidance raised to $4.3-4.34B (25-27% growth) with 22-23% non-GAAP operating margins. However, the stock has surged 30%+ post-earnings to ~$199, near all-time highs at a P/E of ~494x (GAAP). This is the key risk: valuation is extremely stretched. Look for a pullback to build a position at more reasonable entry levels.

Triggers

Entry: Enter on a 10-15% pullback from post-earnings highs to the $170-180 range, which would be closer to pre-earnings analyst PTs. Alternatively, if the stock consolidates in the $190-200 range for 5+ sessions with high volume, confirming the new base, a small position (~1% of portfolio) could be initiated. Do not chase above $200. RBC raised PT to $219 — use that as the upper bound for profit expectations.

Exit: If entered on pullback, take profits at 15-20% gain from entry or near $219 (RBC PT). Exit if Q2 2026 results show revenue growth decelerating below 25% or if the largest customer concentration becomes a headwind. Trim if position exceeds 2% of portfolio.

Invalidation: Revenue growth decelerates below 25% YoY for two consecutive quarters; non-AI customer growth reverses back below 20%; stock breaks below $165 (pre-earnings levels) on fundamental concerns; AI observability spending cycle reverses; major competitive threat from Splunk/New Relic materially erodes market share.

Cited evidence

News